Thomas DiRaimondo - Jan 1, 2024 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)

Role
Chief Scientific Officer
Signature
/s/ Maria Dobek, Attorney-in-Fact
Stock symbol
JANX
Transactions as of
Jan 1, 2024
Transactions value $
$0
Form type
3
Date filed
1/3/2024, 04:45 PM
Next filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding JANX Common Stock 102K Jan 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding JANX Stock option (right to buy) Jan 1, 2024 Common Stock 154K $0.59 Direct F1
holding JANX Stock option (right to buy) Jan 1, 2024 Common Stock 141K $4.21 Direct F2
holding JANX Stock option (right to buy) Jan 1, 2024 Common Stock 256K $10.59 Direct F3
holding JANX Stock option (right to buy) Jan 1, 2024 Common Stock 24K $20.24 Direct F4
holding JANX Stock option (right to buy) Jan 1, 2024 Common Stock 70K $14.02 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the option vested on June 30, 2021 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F2 25% of the shares subject to the option vested on March 10, 2022 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F3 25% of the shares subject to the option vested on May 14, 2022 and the balance of the shares vest in equal monthly installments thereafter over a three year period. The shares subject to this option are early exercisable, subject to the Issuer's right of repurchase.
F4 25% of the shares subject to the option vested on January 1, 2023 and the balance of the shares vest in equal monthly installments thereafter over a three year period.
F5 25% of the shares subject to the option vested on January 1, 2024 and the balance of the shares vest in equal monthly installments thereafter over a three year period.